Kureeckal Ramesh

Kureeckal Ramesh

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2020 in VirusDisease
Verified
Journal Article
Open access
PDF file
DMDipti Mothay
Dipti Mothay
KRKureeckal Ramesh
Kureeckal Ramesh
Recent outbreak of COVID-19 caused by SARS-CoV-2 in December 2019 raised global health concerns. Re-purposing the available protease inhibitor drugs for immediate use in treatment in SARS-CoV-2 infections could improve the currently available clinical management. The current study, aims to predict theoretical structure for protease of COVID-19 and to explore further whether this protein can serve as a target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir, ritonavir and α-ketoamide. While the 3D structure of protease was predicted using SWISS MODEL server, molecular interaction studies between protein and ligands were performed using AutoDock software. The predicted protease model was reasonably good based on reports generated by different validation servers. The study further revealed that all the protease inhibitor drugs got docked with negative dock energy onto the target protein. Molecular interaction studies showed that protease structure had multiple active site residues for remdesivir, while for remaining ligands the structure had only one active site residue each. From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors.

8 September 2015 in Medicinal Chemistry Research
Verified
Journal Article
Closed access
PDF file
BCBahubali M. Chougala
Bahubali M. Chougala
SSSamundeeswari L. Shastri
Samundeeswari L. Shastri
MHMegharaja Holiyachi
Megharaja Holiyachi
LSLokesh Shastri
Lokesh Shastri
SMSunil S. More
Sunil S. More
KRKureeckal Ramesh
Kureeckal Ramesh


1 April 2008 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
KRKureeckal Ramesh
Kureeckal Ramesh
MPMitali Purohit
Mitali Purohit
KMK Mekhala
K Mekhala
MKMrinalini Krishnan
Mrinalini Krishnan
KWKaushiki Wagle
Kaushiki Wagle
SDSudha Deshmukh
Sudha Deshmukh
The present paper reports a bio-computational study carried out with the aim of understanding the binding mode of anti-TB herbal ligands onto the homology modeled structure of fatty acid synthase of Mycobacterium tuberculosis (M.tb) H37Rv. Sequence alignment of β-ketoacyl ACP synthase (KAS) domain of the protein with other related KAS sequences of PDB database revealed high degree of sequence variation. However, the catalytic triad comprising of CHH (cys150-his279-his320) was found to be conserved in the KAS sequence of M.tb H37Rv. The tertiary structure of this protein predicted using genetic algorithm operator in the MODELLER package appeared to give a satisfactory structure for the purpose of studying ligand and substrate binding pockets on the protein. PDB templates complexed with ligands (citric acid and lauric acid) were used for model building. Docking studies carried out with different herbal ligands suggest that, aloe-emodin and nimbin are the best herbal candidates to replace the synthetic drugs ‘thiolactomycin/cerulenin’.

1 March 2014
Verified
Journal Article
Closed access
JDJoy Das
Joy Das
KRKureeckal Ramesh
Kureeckal Ramesh
UMU. Maithri
U. Maithri
MDMutangana Dieudonne
Mutangana Dieudonne
CSC. K. Suresh
C. K. Suresh

15 April 2020 in Research Square
Verified
Preprint
Open access
PDF file
DMDipti Mothay
Dipti Mothay
KRKureeckal Ramesh
Kureeckal Ramesh
Recent outbreak of COVID-19 caused by SARS-CoV-2 in December 2019 raised global health concerns. Re-purposing the available protease inhibitor drugs for immediate use in treatment in SARS‐CoV‐2 infections could improve the currently available clinical management. The current study, aims to predict theoretical structure for protease of COVID-19 and to explore further whether this protein can serve as a target for protease inhibitor drugs such as remdesivir, nelfinavir, lopinavir, ritonavir and α –ketoamide. While the 3D structure of protease was predicted using SWISS MODEL server, molecular interaction studies between protein and ligands were performed using AutoDock software. The predicted protease model was reasonably good based on reports generated by different validation servers. The study further revealed that all the protease inhibitor drugs got docked with negative dock energy onto the target protein. Molecular interaction studies showed that protease structure had multiple active site residues for remdesivir, while for remaining ligands the structure had only one active site residue each. From the output of multiple sequence alignment, it is evident that ligand binding sites were conserved. The current in-silico study thus, provides structural insights about the protease of COVID-19 and also its molecular interactions with some of the known protease inhibitors.